WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Medtronic clears a robotic LigaSure vessel sealer for Hugo, nine months after the robot FDA clears Neptune Medical's Triton 1 robotic colonoscope after a 50-patient study FDA takes pathogen-agnostic sequencing to an advisory panel on November 19 CMS adds heart failure and COPD tracks to the ACCESS model, launching spring 2027 FDA posts a Class I recall of Medtronic's Bravo CF delivery device after 184 serious injuries FDA approves Abbott's Aveir VR Mini, 14 percent shorter than the current Aveir VR Mayo Clinic and Thermo Fisher launch Precure to build a million-specimen molecular dataset FDA opens a reliance portal so foreign regulators can lean on its device decisions Medtronic offers a 7 percent discount to push 80.1% of MiniMed onto its own shareholders Medtronic clears a robotic LigaSure vessel sealer for Hugo, nine months after the robot FDA clears Neptune Medical's Triton 1 robotic colonoscope after a 50-patient study FDA takes pathogen-agnostic sequencing to an advisory panel on November 19 CMS adds heart failure and COPD tracks to the ACCESS model, launching spring 2027 FDA posts a Class I recall of Medtronic's Bravo CF delivery device after 184 serious injuries FDA approves Abbott's Aveir VR Mini, 14 percent shorter than the current Aveir VR Mayo Clinic and Thermo Fisher launch Precure to build a million-specimen molecular dataset FDA opens a reliance portal so foreign regulators can lean on its device decisions Medtronic offers a 7 percent discount to push 80.1% of MiniMed onto its own shareholders

Series B

FIZE Medical takes a first close on a $20M Series B with its Japanese distributor co-leading

MedDevice Startups Staff · 23 hrs ago · 2 min read · Via PR Newswire

FIZE Medical announced the first close of a $20 million Series B on September 17, co-led by Asahi Kasei Medical and Rapha Capital Management. Asahi Kasei Medical is already the exclusive distributor for FIZE in Japan, and the two are extending that arrangement into Europe.

The company sells FIZE kUO, a digital urine output monitor aimed at fluid management in the ICU, where output is still often logged by hand every hour. The system holds CE mark and UKCA certification. FIZE splits its operations between Modiin, Israel and Jericho, New York.

Proceeds go to FIZE Optima, a platform in development that CEO Dror Zerem describes as moving beyond monitoring toward anticipating fluid-related risk. Commercial spend in existing markets takes the rest.

A strategic distributor co-leading a round buys channel and capital in one move. It also gives that strategic a seat at the table on any later sale, which is worth pricing into the term sheet rather than after it.

Questions & Answers

How much did FIZE Medical raise in its Series B?

FIZE Medical announced the first close of a $20 million Series B on September 17, 2026. Asahi Kasei Medical and Rapha Capital Management co-led it.

What does the FIZE kUO system do?

FIZE kUO is FIZE Medical's digital urine output monitor for fluid management in intensive care. It carries CE mark and UKCA certification.

What is Asahi Kasei Medical's relationship with FIZE Medical?

Asahi Kasei Medical co-led FIZE Medical's $20 million Series B first close and is the company's exclusive distributor in Japan, an arrangement the two are extending into Europe.

← Back to Fundraising